FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Katzenstein

Research Profile

Disorders

Living Beings

HIV-1
HIV

Chemicals & Drugs

Geographic Areas

Zimbabwe

Physiology

Procedures

Concepts & Ideas

Viral Load

Phenomena

HIV Seropositivity

Co-author Network

Publications

TOP 3
Katie Mollan; Paul E Sax; Camlin Tierney; Maya Balamane; Ronald J Bosch; Ann C Collier; Eric S Daar; Margaret A Fischl; David Katzenstein; Christina M Lalama
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
Justen Manasa; Marie-Louise Newell; Tulio de Oliveira; Sharon Cassol; David Katzenstein
Primary drug resistance in South Africa: data from 10 years of surveys.
Shanmugam Saravanan; Sathasivam Sivamalar; Sunil S Solomon; Madhavan Vidya; Tokugha Yeptomi; Pachamuthu Balakrishnan; Rami Kantor; David Katzenstein; Nagalingeswaran Kumarasamy; Kenneth H Mayer; Samara Rifkin; Suniti Solomon
Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Katzenstein (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Katie Mollan; Paul E Sax; Camlin Tierney; Maya Balamane; Ronald J Bosch; Ann C Collier; Eric S Daar; Margaret A Fischl; David Katzenstein; Christina M Lalama
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
The Journal of infectious diseases 2012;206(12):1920-30.
2012: Justen Manasa; Marie-Louise Newell; Tulio de Oliveira; Sharon Cassol; David Katzenstein
Primary drug resistance in South Africa: data from 10 years of surveys.
AIDS research and human retroviruses 2012;28(6):558-65.
2012: Shanmugam Saravanan; Sathasivam Sivamalar; Sunil S Solomon; Madhavan Vidya; Tokugha Yeptomi; Pachamuthu Balakrishnan; Rami Kantor; David Katzenstein; Nagalingeswaran Kumarasamy; Kenneth H Mayer; Samara Rifkin; Suniti Solomon
Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012;54(7):995-1000.
2012: Jessica H Brehm; Scott Hammer; David Katzenstein; Dianna L Koontz; John W Mellors; Steven Perry; Yanille Scott; Nicolas Sluis-Cremer
Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase.
PloS one 2012;7(2):e31558.
2012: Rena Patel; Jamie Ratner; Godfrey Woelk; Cheryl Gore Felton; Gerard Kadzirange; David Katzenstein
HIV disclosure patterns, predictors, and psychosocial correlates among HIV positive women in Zimbabwe.
AIDS care 2012;24(3):358-68.
2011: Paul E Sax; Karen Tashima; Camlin Tierney; William C Woodward; Chakra Budhathoki; Ann C Collier; Eric S Daar; Awny Farajallah; Judith Feinberg; Margaret A Fischl; Catherine Godfrey; Belinda Ha; Nasreen C Jahed; David Katzenstein; Katie Mollan; Robert L Murphy; Laurie Myers; James F Rooney
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
The Journal of infectious diseases 2011;204(8):1191-201.
2011: L Thairu; David Katzenstein; D Israelski
Operational challenges in delivering CD4 diagnostics in sub-Saharan Africa.
AIDS care 2011;23(7):814-21.
2011: Mqondisi Tshabalala; Lynn S Zijenah; Justen Manasa; Mary Mucheche; Simbarashe Rusakaniko; Elizabeth Johnston; Gerard Kadzirange; Seble Kassaye; David Katzenstein
Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe.
PloS one 2011;6(6):e21241.
2010: M Kathryn McClellan; Rena Patel; Gerard Kadzirange; Tsungai Chipatod; David Katzenstein
Fertility desires and condom use among HIV-positive women at an antiretroviral roll-out program in Zimbabwe.
African journal of reproductive health 2010;14(2):27-35.
2010: Elizabeth Johnston White; Bryan McColgan; Seble Kassaye; Lynn S Zijenah; David Katzenstein
Unusual five amino acid insert within subtype C HIV-1 envelope contributes to dual-tropism (X4R5).
AIDS (London, England) 2010;24(7):1063-4.
2010: Vici Varghese; Elijah Wang; Farbod Babrzadeh; Michael H Bachmann; Rajin Shahriar; Tommy Liu; Svetlana Jean M Mappala; Baback Gharizadeh; W Jeffrey Fessel; David Katzenstein; Seble Kassaye; Robert W Shafer
Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation.
PloS one 2010;5(6):e10992.
2009: Rena Patel; Seble Kassaye; Cheryl Gore Felton; Grace Wyshak; Gerard Kadzirange; Godfrey Woelk; David Katzenstein
Quality of life, psychosocial health, and antiretroviral therapy among HIV-positive women in Zimbabwe.
AIDS care 2009;21(12):1517-27.
2009: Sudeb C Dalai; Tulio de Oliveira; Gordon W Harkins; Seble G Kassaye; Jennifer Lint; Justen Manasa; Elizabeth Johnston; David Katzenstein
Evolution and molecular epidemiology of subtype C HIV-1 in Zimbabwe.
AIDS (London, England) 2009;23(18):2523-32.
2009: S Saravanan; M Vidya; P Balakrishnan; P Balakrishanan; N Kumarasamy; Sunil S Solomon; S Solomon; Rami Kantor; David Katzenstein; Bharat Ramratnam; Kenneth H Mayer
Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.
Journal of virological methods 2009;159(2):211-6.
2009: Thomas B Campbell; Margaret Borok; Buxton Ndemera; Suzanne Fiorillo; Irene E White; Xing-quan Zhang; Rhoderick N Machekano; David Katzenstein; Lovemore Gwanzura
Lack of evidence for frequent heterosexual transmission of human herpesvirus 8 in Zimbabwe.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(11):1601-8.
2009: Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.
Journal of virology 2009;83(11):5592-605.
2009: Madhavan Vidya; Shanmugam Saravanan; Shanmugasundaram Uma; Nagalingeswaran Kumarasamy; Solomon S Sunil; Rami Kantor; David Katzenstein; Bharat Ramratnam; Kenneth H Mayer; Solomon Suniti; Pachamuthu Balakrishnan
Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India.
Antiviral therapy 2009;14(7):1005-9.
2008: D Bhattacharya; David Katzenstein; A Wong; Dennis Israelski; JC Imperial; Emmet B Keeffe; R M Donovan
Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance.
International journal of STD & AIDS 2008;19(11):780-1.
2008: Jeffrey Anderson; Hongyu Jiang; Xiao Ding; Leslie Petch; Terri Journigan; Susan A Fiscus; Richard Haubrich; David Katzenstein; Ronald Swanstrom; Roy M Gulick
Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.
AIDS research and human retroviruses 2008;24(5):685-94.
2007: Giovanni Schifitto; J Zhang; Scott R Evans; Ned Sacktor; David Simpson; LL Millar; V L Hung; Eric N Miller; E Smith; Ronald J Ellis; Victor Valcour; Elyse Singer; Christina M Marra; Dennis L Kolson; J Weihe; R Remmel; David Katzenstein; David B Clifford
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment.
Neurology 2007;69(13):1314-21.
2007: Seble Kassaye; Esther Lee; Rami Kantor; Elizabeth Johnston; Mark Winters; Lynn S Zijenah; Patrick Mateta; David Katzenstein
Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.
AIDS research and human retroviruses 2007;23(8):1055-61.
2007: Richard Haubrich; Hongyu Jiang; Ronald Swanstrom; Michael Bates; David Katzenstein; Leslie Petch; Courtney V Fletcher; Susan A Fiscus; Roy M Gulick
Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.
HIV clinical trials 2007;8(2):63-7.
2007: Vivian Levy; Diane Prentiss; Gladys Balmas; Sanny Chen; Dennis Israelski; David Katzenstein; Kimberly Page-Shafer
Factors in the delayed HIV presentation of immigrants in Northern California: implications for voluntary counseling and testing programs.
Journal of immigrant and minority health / Center for Minority Public Health 2007;9(1):49-54.
2006: Susanne P Martin-Herz; Avinash K Shetty; Mary T Bassett; Catherine Ley; Miriam Mhazo; Sostain Moyo; Arnd M Herz; David Katzenstein
Perceived risks and benefits of HIV testing, and predictors of acceptance of HIV counselling and testing among pregnant women in Zimbabwe.
International journal of STD & AIDS 2006;17(12):835-41.
2006: David Katzenstein
Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa.
The Journal of infectious diseases 2006;194 Suppl 1():S45-50.
2006: Keith Henry; David Katzenstein; Deborah Weng Cherng; Hernan Valdez; William G Powderly; Michelle Blanchard Vargas; Nasreen C Jahed; Jeffrey M Jacobson; Laurie S Myers; John L Schmitz; Mark Winters; Pablo Tebas
A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.
Journal of acquired immune deficiency syndromes (1999) 2006;42(2):140-8.
2005: Pachamuthu Balakrishnan; Nagalingeswaran Kumarasamy; Rami Kantor; Suniti Solomon; Sundararajan Vidya; Kenneth H Mayer; Michael Newstein; Sadras Panchatcharam Thyagarajan; David Katzenstein; Bharat Ramratnam
HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India.
AIDS research and human retroviruses 2005;21(4):301-5.
2005: Clive Gray; Carolyn Williamson; Helba Bredell; Adrian Puren; Xiaohua Xia; Ruben Filter; Lynn S Zijenah; Huyen Cao; Lynn Morris; Eftyhia Vardas; Mark Colvin; Glenda Gray; James McIntyre; ROSEMARY MUSONDA; Susan Allen; David Katzenstein; Mike Mbizo; Newton Kumwenda; Taha E Taha; Salim Abdool Karim; Jorge Flores; Haynes W Sheppard
Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa.
AIDS research and human retroviruses 2005;21(4):285-91.
2005: Rami Kantor; Robert W Shafer; David Katzenstein
The HIV-1 Non-subtype B Workgroup: an international collaboration for the collection and analysis of HIV-1 non-subtype B data.
MedGenMed : Medscape general medicine 2005;7(1):71.
2004: Agatha Masemola; Tumelo Mashishi; Greg Khoury; Helba Bredell; Maria Paximadis; Tiyani Mathebula; Debra Barkhan; Adrian Puren; Eftyhia Vardas; Mark Colvin; Lynn S Zijenah; David Katzenstein; ROSEMARY MUSONDA; Susan Allen; Newton Kumwenda; Taha E Taha; Glenda Gray; James McIntyre; Salim Abdool Karim; Haynes W Sheppard; Clive Gray
Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(7):4607-17.
2004: Ronald Swanstrom; Ronald J Bosch; David Katzenstein; Hailong Cheng; Hongyu Jiang; Nicholas S Hellmann; Richard Haubrich; Susan A Fiscus; Courtney V Fletcher; Edward P Acosta; Roy M Gulick
Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.
The Journal of infectious diseases 2004;190(5):886-93.
2004: Rami Kantor; Robert W Shafer; Stephen E Follansbee; Jonathan Taylor; David Shilane; Leo Hurley; Dong Phuong Nguyen; David Katzenstein; W Jeffrey Fessel
Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy.
AIDS (London, England) 2004;18(11):1503-11.
2004: Courtney V Fletcher; Hongyu Jiang; Richard C Brundage; Edward P Acosta; Richard Haubrich; David Katzenstein; Roy M Gulick
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
The Journal of infectious diseases 2004;189(7):1176-84.
2004: Agatha Masemola; Tumelo Mashishi; Greg Khoury; Phineas Mohube; Pauline Mokgotho; Eftyhia Vardas; Mark Colvin; Lynn S Zijenah; David Katzenstein; ROSEMARY MUSONDA; Susan Allen; Newton Kumwenda; Taha E Taha; Glenda Gray; James McIntyre; Salim Abdool Karim; Haynes W Sheppard; Clive Gray
Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load.
Journal of virology 2004;78(7):3233-43.
2004: David Katzenstein
The longer the better? Four years of durable, initially boosted protease treatment.
AIDS (London, England) 2004;18(5):811-3.
2004: Rami Kantor; David Katzenstein
Drug resistance in non-subtype B HIV-1.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2004;29(3):152-9.
2003: Hongyu Jiang; Steven G Deeks; Daniel R Kuritzkes; Marc Lallemant; David Katzenstein; Mary Albrecht; Victor DeGruttola
Assessing resistance costs of antiretroviral therapies via measures of future drug options.
The Journal of infectious diseases 2003;188(7):1001-8.
2003: David Katzenstein; Marie Laga; Jean-Paul Moatti
The evaluation of the HIV/AIDS drug access initiatives in Côte d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa.
AIDS (London, England) 2003;17 Suppl 3():S1-4.
2003: Rami Kantor; David Katzenstein
Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.
AIDS reviews 2003;5(1):25-35.
2002: Roy M Gulick; X Joan Hu; Susan A Fiscus; Courtney V Fletcher; Richard Haubrich; Hailong Cheng; Edward Acosta; Stephen W Lagakos; Ronald Swanstrom; William Freimuth; Snyder Sally; Charlotte Mills; Margaret A Fischl; Carla Pettinelli; David Katzenstein
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.
The Journal of infectious diseases 2002;186(5):626-33.
2002: Rhoderick Machekano; Mary Bassett; Willi McFarland; David Katzenstein
Clinical signs and symptoms in the assessment of immunodeficiency in men with subtype C HIV infection in Harare, Zimbabwe.
HIV clinical trials 2002;3(2):148-54.
2002: Jorge Casseb; David Katzenstein; Mark Winters; Luis Brigido; Alberto J S Duarte; R Michael Hendry
Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica ... [et al.] 2002;35(3):369-75.
2002: Michael Polydefkis; Constantin T Yiannoutsos; Bruce A Cohen; H Hollander; Giovanni Schifitto; David B Clifford; David M Simpson; David Katzenstein; Sharon L Shriver; Peter Hauer; AMANDA BROWN; Anna-Bettina Haidich; Lauren R Moo; justin charles mcarthur
Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy.
Neurology 2002;58(1):115-9.
2001: D M Simpson; David Katzenstein; Anna-Bettina Haidich; D Millington; Constantin T Yiannoutsos; Giovanni Schifitto; justin charles mcarthur
Plasma carnitine in HIV-associated neuropathy.
AIDS (London, England) 2001;15(16):2207-8.
2001: Giovanni Schifitto; Constantin T Yiannoutsos; David M Simpson; B T Adornato; Elyse J Singer; H Hollander; Christina M Marra; M Rubin; Bruce A Cohen; T Tucker; Igor J Koralnik; David Katzenstein; Anna-Bettina Haidich; M E Smith; Sharon L Shriver; LL Millar; David B Clifford; justin charles mcarthur
Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy.
Neurology 2001;57(7):1313-6.
2001: Nancy S Shulman; Andrew R Zolopa; Douglas J Passaro; Robert W Shafer; W Huang; David Katzenstein; Dennis Israelski; Nicholas S Hellmann; Christos J Petropoulos; Jeannette M Whitcomb
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
AIDS (London, England) 2001;15(9):1125-32.
2000: H Guevara; Elizabeth Johnston; Lynn S Zijenah; O Tobaiwa; P Mason; Christopher H Contag; Kassam Mahomed; M Hendry; David Katzenstein
Prenatal transmission of subtype C HIV-1 in Zimbabwe: HIV-1 RNA and DNA in maternal and cord blood.
Journal of acquired immune deficiency syndromes (1999) 2000;25(5):390-7.
2000: Courtney V Fletcher; Edward P Acosta; Hailong Cheng; Richard Haubrich; Margaret A Fischl; Ralph H Raasch; Charlotte Mills; X Joan Hu; David Katzenstein; R P Remmel; Roy M Gulick
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
AIDS (London, England) 2000;14(16):2495-501.
2000: David Katzenstein
Vertical transmission of HIV in Africa: diagnostic testing and new interventions.
HIV clinical trials 2000;1(3):51-7.
2000: Roy M Gulick; X Joan Hu; Susan A Fiscus; Courtney V Fletcher; Richard Haubrich; Hailong Cheng; Edward Acosta; Stephen W Lagakos; Ronald Swanstrom; William Freimuth; Snyder Sally; Charlotte Mills; Margaret A Fischl; C Pettinelli; David Katzenstein
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.
The Journal of infectious diseases 2000;182(5):1375-84.
2000: Thomas M Lampinen; Shalini L Kulasingam; J Min; Margaret Borok; Lovemore Gwanzura; J Lamb; Kassam Mahomed; Godfrey B Woelk; KB Strand; Marnix Bosch; Daniel C Edelman; Niel T Constantine; David Katzenstein; Michelle A Williams
Detection of Kaposi's sarcoma-associated herpesvirus in oral and genital secretions of Zimbabwean women.
The Journal of infectious diseases 2000;181(5):1785-90.
2000: justin charles mcarthur; Constantin T Yiannoutsos; David M Simpson; B T Adornato; Elyse J Singer; H Hollander; C Marra; M Rubin; Bruce A Cohen; T Tucker; Bradford A Navia; Giovanni Schifitto; David Katzenstein; C Rask; L Zaborski; M E Smith; Sharon L Shriver; LL Millar; David B Clifford; I J Karalnik
A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291.
Neurology 2000;54(5):1080-8.
2000: Victor DeGruttola; L Dix; Richard T D'Aquila; D Holder; A Phillips; Mounir Ait-Khaled; J Baxter; Philippe Clevenbergh; S Hammer; R Harrigan; David Katzenstein; R Lanier; M Miller; Michael F Para; S Yerly; Andrew R Zolopa; J Murray; A Patick; Veronica Miller; S Castillo; Louise Pedneault; John Mellors
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.
Antiviral therapy 2000;5(1):41-8.
1999: Andrew R Zolopa; Robert W Shafer; Ann Warford; Jose G Montoya; P Hsu; David Katzenstein; Thomas C Merigan; Bradley Efron
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.
Annals of internal medicine 1999;131(11):813-21.
1999: Willi McFarland; Lovemore Gwanzura; Mary T Bassett; Rhoderick Machekano; Ahmed Latif; Catherine Ley; Julie Parsonnet; R L Burke; David Katzenstein
Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers.
The Journal of infectious diseases 1999;180(5):1459-65.
1999: D Heather Watts; C Spino; L Zaborski; David Katzenstein; S Hammer; Constance Benson
Comparison of gynecologic history and laboratory results in HIV-positive women with CD4+ lymphocyte counts between 200 and 500 cells/microl and below 100 cells/microl.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1999;20(5):455-62.
1998: H Kastrissios; J R Suárez; S Hammer; David Katzenstein; Terrence F Blaschke
The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker.
AIDS (London, England) 1998;12(17):2305-11.
1998: H Kastrissios; J R Suárez; David Katzenstein; P Girard; Lewis B Sheiner; Terrence F Blaschke
Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial.
AIDS (London, England) 1998;12(17):2295-303.
1998: S Ray; Ahmed Latif; Rhoderick Machekano; David Katzenstein
Sexual behaviour and risk assessment of HIV seroconvertors among urban male factory workers in Zimbabwe.
Social science & medicine (1982) 1998;47(10):1431-43.
1998: Lynn S Zijenah; Michael T Mbizvo; J Kasule; Kusum J Nathoo; Marshall W Munjoma; Kassam Mahomed; Yvonne Maldonado; Simon Madzime; David Katzenstein
Mortality in the first 2 years among infants born to human immunodeficiency virus-infected women in Harare, Zimbabwe.
The Journal of infectious diseases 1998;178(1):109-13.
1998: D Zipeto; C Hong; G Gerna; M Zavattoni; David Katzenstein; Thomas C Merigan; Lucy Rasmussen
Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients.
AIDS research and human retroviruses 1998;14(6):533-6.
1998: Rhoderick Machekano; Willi McFarland; Michael T Mbizvo; Mary T Bassett; David Katzenstein; Ahmed Latif
Impact of HIV counselling and testing on HIV seroconversion and reported STD incidence among male factory workers in Harare, Zimbabwe.
The Central African journal of medicine 1998;44(4):98-102.
1998: C Goulston; Willi McFarland; David Katzenstein
Human immunodeficiency virus type 1 RNA shedding in the female genital tract.
The Journal of infectious diseases 1998;177(4):1100-3.
1998: Lovemore Gwanzura; Willi McFarland; D Alexander; R L Burke; David Katzenstein
Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe.
The Journal of infectious diseases 1998;177(2):481-4.
1997: SK Kundu; David Katzenstein; F T Valentine; C Spino; Bradley Efron; Thomas C Merigan
Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;15(4):269-74.
1997: Michael T Mbizvo; Ahmed Latif; Rhoderick Machekano; W MacFarland; Mary T Bassett; S Ray; David Katzenstein
HIV seroconversion among factory workers in Harare: who is getting newly infected?
The Central African journal of medicine 1997;43(5):135-9.
1996: C Goulston; E Stevens; D Gallo; James I Mullins; Carl Hanson; David Katzenstein
Human immunodeficiency virus in plasma and genital secretions during the menstrual cycle.
The Journal of infectious diseases 1996;174(4):858-61.
1996: Mark Holodniy; David Katzenstein; L Mole; M Winters; Thomas C Merigan
Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.
The Journal of infectious diseases 1996;174(4):854-7.
1996: Michael T Mbizvo; Rhoderick Machekano; W McFarland; S Ray; Mary T Bassett; Ahmed Latif; David Katzenstein
HIV seroincidence and correlates of seroconversion in a cohort of male factory workers in Harare, Zimbabwe.
AIDS (London, England) 1996;10(8):895-901.
1996: Fred Valentine; S Kundu; P A Haslett; David Katzenstein; Laurel Beckett; C Spino; M Borucki; M Vasquez; G Smith; J Korvick; J Kagan; Thomas C Merigan
A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).
The Journal of infectious diseases 1996;173(6):1336-46.
1995: Ann C Collier; Robert W Coombs; David Katzenstein; Mark Holodniy; J Gibson; J Mordenti; Allen E Izu; AM Duliege; A J Ammann; T Merigan
Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10(2):150-6.
1994: Michael T Mbizvo; S Ray; Mary T Bassett; W McFarland; Rhoderick Machekano; David Katzenstein
Condom use and the risk of HIV infection: who is being protected?
The Central African journal of medicine 1994;40(11):294-9.
1993: Jose G Montoya; R Wood; David Katzenstein; M Holodny; Thomas C Merigan
Peripheral blood mononuclear cell human immunodeficiency virus type 1 proviral DNA quantification by polymerase chain reaction: relationship to immunodeficiency and drug effect.
Journal of clinical microbiology 1993;31(10):2692-6.
1993: Mark Holodniy; David Katzenstein; M Winters; J Montoya; R Shafer; M Kozal; M Ragni; Thomas C Merigan
Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.
Journal of acquired immune deficiency syndromes 1993;6(4):366-9.
1992: SK Kundu; David Katzenstein; L E Moses; Thomas C Merigan
Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(23):11204-8.
1992: J Mohle-Boetani; S K Akula; Mark Holodniy; David Katzenstein; G Garcia
The sulfone syndrome in a patient receiving dapsone prophylaxis for Pneumocystis carinii pneumonia.
The Western journal of medicine 1992;156(3):303-6.
1991: Mark Holodniy; S Kim; David Katzenstein; M Konrad; E Groves; Thomas C Merigan
Inhibition of human immunodeficiency virus gene amplification by heparin.
Journal of clinical microbiology 1991;29(4):676-9.